Is pneumonia serious after taking Platinib?

Platinib, as a treatment for RET fusion-positive cancers, has shown significant efficacy in clinical trials, but some adverse reactions may occur during its use, among which pneumonia is one of the more concerning issues.

Pneumonitis was indeed listed as a possible adverse reaction in clinical trials of Platinib. Specifically, infectious pneumonia, atypical pneumonia, pulmonary infection, and bacterial pneumonia have been reported. However, specific incidence rates vary based on factors such as patient population, duration of treatment, and comorbidities.

In most cases, pneumonia caused by platinib may be mild to moderate, and patients may experience symptoms such as cough, fever, and difficulty breathing. This type of pneumonia can usually be controlled with appropriate medical management, such as using antibiotics, adjusting medication doses, or suspending treatment.

Although relatively rare, severe pneumonia can occur with platinib. This type of pneumonia may require more aggressive treatment, including hospitalization, intravenous fluids, and oxygen therapy. In extreme cases, severe pneumonia can even be life-threatening.

For mild to moderate pneumonia, your doctor may recommend a lower dose of platinib to reduce irritation to the lungs. This is usually done with close observation of the patient's symptoms.

If pneumonia symptoms continue to worsen or signs of severe pneumonia appear, your doctor may recommend pausing or permanently discontinuing Platinib. This is to ensure patient safety and prevent further deterioration of the condition.

To reduce the risk of pneumonia while taking platinib, patients should follow their doctor's recommendations and have regular physical exams. In addition, maintaining good living habits, enhancing immunity, and avoiding direct contact with sources of infection are also effective preventive measures.